Pneumococcal Disease: Pathogenesis, Treatment, and Prevention

Infectious Diseases in Clinical Practice

Volumn 12, Issue 2, 2004, Pages 93-98

  McDaniel, Larry S ^a   Swiatlo, Edwin ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

23 VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE; ADHESIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; DEXAMETHASONE; DNA VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MACROLIDE; MEMBRANE PROTEIN; PENICILLIN G; PNEUMOCOCCAL ADHESIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE BURDEN; DRUG EFFICACY; DRUG MEGADOSE; GENETIC TRANSFORMATION; GENOMICS; HEALTH CARE COST; HUMAN; IMMUNOCHEMISTRY; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; SEPSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 1642353398     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000121024.62151.c9     Document Type: Article

References (49)

1. Fedson DS, Musher DM. Pneumococcal vaccine. In: Mortimer JEA, ed. Vaccines. 2nd ed. Philadelphia, PA: WB Saunders; 1994:517-563.
2. Berman S, McIntosh K. Selective primary health care: strategies for control of disease in the developing world: XXI. Acute respiratory infections. Rev Infect Dis. 1985;7:674-691.
3. Arnold KE, Leggiadro RJ, Breiman RF, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr. 1996;128:757-764.
4. Klein JO. Otitis media. Clin Infect Dis. 1994;19:823-833.
5. Tan TQ, Mason EO, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110:1-6.
6. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112-1121.
7. Ertugrul N, Rodriguez-Barradas MC, Musher DM, et al. BOX-polymerase chain reaction-based DNA analysis of nonserotypeable Streptococcus pneumoniae implicated in outbreaks of conjunctivitis. J Infect Dis. 1997;176:1401-1405.
8. Dillard JP, Yother J. Genetic and molecular characterization of capsular polysaccharide biosynthesis in Streptococus pneumoniae type 3. Mol Microbiol. 1994;12(6):959-972.
9. Briles DE, Crain MJ, Gray BM, et al. A strong association between capsular type and mouse virulence among human isolates of Streptococcus pneumoniae. Infect Immun. 1992;60:111-116.
10. Austrian R, MacLeod CM. A type-specific protein from pneumococcus. J Exp Med. 1949;89:439-450.
11. McDaniel LS, Scott G, Kearney JF, et al. Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med. 1984;160:386-397.
12. McDaniel LS, Yother J, Vijayakumar M, et al. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp Med. 1987;165:381-394.
13. McDaniel LS, Sheffield JS, Delucchi P, et al. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun. 1991;59:222-228.
14. Anders H, Roche H, Mirza S, et al. Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun. 2001;69:3372-3381.
15. McDaniel LS, McDaniel DO, Hollingshead SK, et al. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Iñfect Immun. 1998;10:4748-4754.
16. McDaniel LS, McDaniel DO. Analysis of the gene encoding type 12 PspA of Streptococcus pneumoniae 5668. In: Brown F, ed. Genetics of Streptococci, Enterococci, and Lactococci. Vol 85. Basel: Karger; 1995:283-286.
17. Yother J, White JM. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol. 1994;176(10): 2976-2985.
18. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, et al. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun. 2002;70:2526-2534.
19. Dave S, Brooks-Walter A, Pangburn MK, et al. PspC, a pneumococcal surface protein, binds human factor H. Infect Immun. 2001;69:3435-3437.
20. Tseng H-J, McEwan AG, Paton JC, et al. Virulence of Streptococcus pneumoniae: PsaA mutants are hypersensitive to oxidative stress. Infect Immun. 2002;70:1635-1639.
21. Rogers PD, Thornton J, Barker KS, et al. Pneumolysin-dependent and -independent gene expression identified by cDNA microarray analysis in THP-1 human mononuclear cells stimulated by Streptococcus pneumoniae. Infect Immun. 2003;71:2087-2094.
22. Zeiger RS. Prospects for ancillary treatment of sinusitis in the 1990s. J Allergy Clin Immunol. 1992;90:478-495.
23. Partnership SaA. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol-Head Neck Surg. 2000;123:S1-S32.
24. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
25. Barlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
26. Standards NCCLs. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
27. Barlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
28. Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 2000;31:1008-1011.
29. Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis. 1991;164:302-306.
30. Munoz R, Musser JM, Crain MJ, et al. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis. 1992;15:112-118.
31. Coffey TJ, Dowson CG, Daniels M, et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol. 1991;5:2255-2260.
32. Smith AM, Klugman KP. Three predominant clones identified within penicillin-resistant South African isolates of Streptococcus pneumoniae. Microb Drug Resist. 1997;3:385-389.
33. Shi Z-Y, Enright MC, Wilkinson P, et al. Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequencing typing. J Clin Microbiol. 1998;36:3514-3519.
34. Jabes D, Nachman S, Tomasz A. Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci. J Infect Dis. 1989;159:16-25.
35. McGee L, McDougal L, Zhou J, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol. 2001;39(7):2565-2571.
36. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
37. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis. 2000;181:369-373.
38. Sloas MM, Barrett FF, Chesney PJ, et al. Ceftriaxone treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 1992;11:662-666.
39. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med. 1997;336:708-716.
40. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
41. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453-1460.
42. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-1755.
43. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systemic review of clinical effectiveness in adults. Vaccine. 2002;20:2166-2173.
44. Dagan R. Immunization with a pneumococcal 7-valent conjugate vaccine. Int. J Clin Pract. 2002;56:287-291.
45. Lipsitch M. Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvacinne serotypes. Am J Epidemiol. 2001;154:85-92.
46. Briles DE, Hollingshead SK, Nabors GS, et al. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine. 2001;19:S87-S95.
47. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae. J Infect Dis. 2000;182:1694-1701.
48. Bosarge JR, Watt JM, McDaniel DO, et al. Genetic immunization with the region encoding the α-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun. 2001;69:5456-5463.
49. Swiatlo E, Ware, D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol. 2003;38:1-7.